Cellectar Biosciences (CLRB) Common Equity (2010 - 2026)
Cellectar Biosciences (CLRB) posted Common Equity of $8.5 million for Q4 2025, up 6.75% sequentially from $8.0 million in Q3 2025, and down 40.28% YoY from $14.3 million in Q4 2024.
Cellectar Biosciences (CLRB) Common Equity (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Common Equity for 16 years, with the latest figure at $8.5 million in Q4 2025.
- Quarterly Common Equity fell 40.28% year-over-year to $8.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.5 million (down 40.28% YoY) and the FY2025 annual result came in at $8.5 million, down 40.28% from the prior year.
- Common Equity climbed to $8.5 million in Q4 2025 per CLRB's latest filing, from $8.0 million in the prior quarter.
- Over five years, Common Equity peaked at $49.8 million in Q1 2021 and troughed at -$28.0 million in Q3 2023.
- A 5-year average of $12.8 million and a median of $11.6 million in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2021 and 2023: Common Equity jumped 848.84% in 2021, then tumbled 360.02% in 2023.
- Over 5 years, Common Equity stood at $29.1 million in 2021, then sank by 71.95% to $8.2 million in 2022, then plunged by 285.93% to -$15.2 million in 2023, then surged by 194.3% to $14.3 million in 2024, then tumbled by 40.28% to $8.5 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $8.5 million, $8.0 million, and $6.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Cellectar Biosciences | 6.63 Mn | 6.63 Mn | - | 29.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.87 Mn |
| Dec 31, 2025 | 8.54 Mn |
| Sep 30, 2025 | 8.00 Mn |
| Jun 30, 2025 | 6.09 Mn |
| Mar 31, 2025 | 8.25 Mn |
| Dec 31, 2024 | 14.29 Mn |
| Sep 30, 2024 | 15.16 Mn |
| Jun 30, 2024 | 12.38 Mn |
| Mar 31, 2024 | 12.50 Mn |
| Dec 31, 2023 | -15.16 Mn |
| Sep 30, 2023 | -28.00 Mn |
| Jun 30, 2023 | -8.39 Mn |
| Mar 31, 2023 | 1.37 Mn |
| Dec 31, 2022 | 8.15 Mn |
| Sep 30, 2022 | 10.77 Mn |
| Jun 30, 2022 | 17.91 Mn |
| Mar 31, 2022 | 23.13 Mn |
| Dec 31, 2021 | 29.06 Mn |
| Sep 30, 2021 | 38.59 Mn |
| Jun 30, 2021 | 43.98 Mn |